Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab

BACKGROUND AND OBJECTIVES: B cell–depleting antibodies were proven as effective strategy for the treatment of relapsing multiple sclerosis (RMS). The monoclonal antibody ocrelizumab was approved in 2017 in the United States and in 2018 in the European Union, but despite proven efficacy in randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfeuffer, Steffen, Rolfes, Leoni, Ingwersen, Jens, Pul, Refik, Kleinschnitz, Konstanze, Korsen, Melanie, Räuber, Saskia, Ruck, Tobias, Schieferdecker, Simon, Willison, Alice Grizzel, Aktas, Orhan, Kleinschnitz, Christoph, Hartung, Hans-Peter, Kappos, Ludwig, Meuth, Sven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091366/
https://www.ncbi.nlm.nih.gov/pubmed/37041077
http://dx.doi.org/10.1212/NXI.0000000000200104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091366/
https://www.ncbi.nlm.nih.gov/pubmed/37041077
http://dx.doi.org/10.1212/NXI.0000000000200104

Ejemplares similares